Home > Neurology > MS Virtual 2020 > Miscellaneous Topics > Disease activity during pregnancy in a modern MS cohort

Disease activity during pregnancy in a modern MS cohort


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
MS Virtual 2020
Women with relapsing-remitting MS treated with moderate- or high-efficacy disease-modifying treatment (DMT) are at greater risk of relapse during pregnancy [1]. Apparently, immunomodulatory changes during pregnancy are not sufficient to suppress MS disease activity among these women. This is of great clinical interest because pregnancy has historically been associated with a reduced risk of relapse. The presented study aimed to compare the characteristics and relapse rates of a modern cohort of women on different classes of DMT (low-, moderate-, and high-efficacy) before conception, and to determine factors that predicted relapse. The study included data of 1,640 pregnancies in 2011-2019, conceived from 1,452 women. DMT use in the year before conception was no DMT (n=346), low-efficacy (n=845), moderate-efficacy (n=207), and high-efficacy (n=242). EDSS ≥2 at the time of conception was more common in higher-efficacy DMT groups (high-efficacy DMT 41.3...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on